{"id":742082,"date":"2011-10-05T06:35:00","date_gmt":"2011-10-05T06:35:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/"},"modified":"2026-08-10T13:01:16","modified_gmt":"2026-08-10T17:01:16","slug":"fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/","title":{"rendered":"FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known outside the United States and Canada as MSD, and<br \/>\n      ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), today announced that the<br \/>\n      U.S. Food and Drug Administration (FDA) has accepted for filing and<br \/>\n      review the New Drug Application (NDA) for ridaforolimus, an<br \/>\n      investigational oral mTOR inhibitor under development for the treatment<br \/>\n      of metastatic soft-tissue or bone sarcomas in patients who had a<br \/>\n      favorable response to chemotherapy. The FDA assigned a Standard review<br \/>\n      classification to this application.\n    <\/p>\n<p>\n      Merck and ARIAD previously announced that the European Medicines Agency<br \/>\n      had accepted the marketing authorization application for ridaforolimus.<br \/>\n      As part of an exclusive license agreement with ARIAD, Merck is<br \/>\n      responsible for the development and worldwide commercialization of<br \/>\n      ridaforolimus in oncology. ARIAD intends to co-promote ridaforolimus in<br \/>\n      the United States.\n    <\/p>\n<p>\n      <b>About Sarcoma<\/b>\n    <\/p>\n<p>\n      Sarcomas are a group of cancers of connective tissue of the body for<br \/>\n      which there are currently limited treatment options. Sarcomas can arise<br \/>\n      anywhere in the body and are divided into two main groups \u2013 bone tumors<br \/>\n      and soft-tissue sarcomas.\n    <\/p>\n<p>\n      <b>About Ridaforolimus<\/b>\n    <\/p>\n<p>\n      Ridaforolimus is an investigational targeted and potent small-molecule<br \/>\n      inhibitor of the protein mTOR, a protein that acts as a central<br \/>\n      regulator of protein synthesis, cell proliferation, cell cycle<br \/>\n      progression and cell survival, integrating signals from proteins, such<br \/>\n      as PI3K, AKT and PTEN, known to be important to malignancy.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to Oncology<\/b>\n    <\/p>\n<p>\n      Merck is committed to advancing all aspects of cancer care \u2013 prevention,<br \/>\n      treatment and supportive care. Through strong internal research<br \/>\n      capabilities, selective alliances and acquisitions, and enabling<br \/>\n      technologies, Merck is looking to lead in the discovery, development and<br \/>\n      delivery of anticancer therapies.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=50274408&amp;lan=en-US&amp;anchor=www.merck.com+and+connect+with+us+on+Twitter%2C+Facebook+and+YouTube.&amp;index=1&amp;md5=383b2ce2a5b471215c8b07915435cc18\"><span class=\"bwuline\">www.merck.com<\/span><br \/>\n      and connect with us on Twitter, Facebook and YouTube.<\/a>\n    <\/p>\n<p>\n      <b>About ARIAD<\/b>\n    <\/p>\n<p>\n      ARIAD Pharmaceuticals, Inc. is an emerging global oncology company<br \/>\n      focused on the discovery, development and commercialization of medicines<br \/>\n      to transform the lives of cancer patients. ARIAD\u2019s approach to<br \/>\n      structure-based drug design has led to three internally discovered,<br \/>\n      molecularly targeted product candidates for drug-resistant and<br \/>\n      difficult-to-treat cancers, including certain forms of chronic myeloid<br \/>\n      leukemia, soft tissue and bone sarcomas and non-small cell lung cancer.<br \/>\n      For additional information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ariad.com&amp;esheet=50274408&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.ariad.com.&amp;index=2&amp;md5=6c1a49cecb5904916a5c0f657bee7cef\"><span class=\"bwuline\">http:\/\/www.ariad.com<\/span>.<\/a>\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes &#8220;forward-looking statements&#8221; within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company&#8217;s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck&#8217;s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and health care legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck&#8217;s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck&#8217;s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the United States and internationally and the exposure to<br \/>\n      litigation and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck&#8217;s 2010 Annual Report on Form 10-K and the company&#8217;s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC&#8217;s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50274408&amp;lan=en-US&amp;anchor=www.sec.gov%29.&amp;index=3&amp;md5=bc7084c809fd3e2f24620d17d45c572a\"><span class=\"bwuline\">www.sec.gov<\/span>).<\/a>\n    <\/p>\n<p>\n      <b>ARIAD Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This press release contains &#8220;forward-looking statements&#8221; including, but<br \/>\n      not limited to, statements relating to clinical data for ridaforolimus<br \/>\n      in the treatment of metastatic soft-tissue and bone sarcomas.<br \/>\n      Forward-looking statements are based on management&#8217;s expectations and<br \/>\n      are subject to certain factors, risks and uncertainties that may cause<br \/>\n      actual results, outcome of events, timing and performance to differ<br \/>\n      materially from those expressed or implied by such statements. These<br \/>\n      risks and uncertainties include, but are not limited to, results of<br \/>\n      clinical studies of the Company&#8217;s product candidates, timing and<br \/>\n      acceptance of regulatory filings for drug approval, and other factors<br \/>\n      detailed in the Company&#8217;s public filings with the U.S. Securities and<br \/>\n      Exchange Commission. The information contained in this press release is<br \/>\n      believed to be current as of the date of original issue. The Company<br \/>\n      does not intend to update any of the forward-looking statements after<br \/>\n      the date of this document to conform these statements to actual results<br \/>\n      or to changes in the Company&#8217;s expectations, except as required by law.\n    <\/p>\n<p>\n      Photos\/Multimedia Gallery Available: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D50018533%26lang%3Den&amp;esheet=50274408&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D50018533%26lang%3Den&amp;index=4&amp;md5=74b437290a5cb29ec9bd1f56ee70b5f4\"><span class=\"bwuline\">http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=50018533&amp;lang=en<\/span><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120510007091r1&amp;sid=sfsite1&amp;distro=nx\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 908-423-3046<br \/>or<br \/>Noreen        Verbrugge, 908-423-6301<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>ARIAD Pharmaceuticals<br \/>Media:<br \/>Liza        Heapes, 617-621- 2315<br \/>or<br \/>Investors:<br \/>Maria E. Cantor,        617-621-2208     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for ridaforolimus, an investigational oral mTOR inhibitor under development for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy. The FDA assigned a Standard review classification to this application. Merck and ARIAD previously announced that the European Medicines Agency had accepted the marketing authorization application for ridaforolimus. As part of an exclusive license agreement with ARIAD, Merck is responsible for the development and worldwide commercialization of ridaforolimus in oncology. ARIAD intends to co-promote ridaforolimus in the United States. About Sarcoma Sarcomas are a group of cancers of connective tissue of the body for which there are currently limited<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742082","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for ridaforolimus, an investigational oral mTOR inhibitor under development for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy. The FDA assigned a Standard review classification to this application. Merck and ARIAD previously announced that the European Medicines Agency had accepted the marketing authorization application for ridaforolimus. As part of an exclusive license agreement with ARIAD, Merck is responsible for the development and worldwide commercialization of ridaforolimus in oncology. ARIAD intends to co-promote ridaforolimus in the United States. About Sarcoma Sarcomas are a group of cancers of connective tissue of the body for which there are currently limited\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:16+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120510007091r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\\\/\",\"name\":\"FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120510007091r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2011-10-05T06:35:00+00:00\",\"dateModified\":\"2026-08-10T17:01:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120510007091r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120510007091r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor - Merck.com","og_description":"Merck (NYSE:MRK), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for ridaforolimus, an investigational oral mTOR inhibitor under development for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy. The FDA assigned a Standard review classification to this application. Merck and ARIAD previously announced that the European Medicines Agency had accepted the marketing authorization application for ridaforolimus. As part of an exclusive license agreement with ARIAD, Merck is responsible for the development and worldwide commercialization of ridaforolimus in oncology. ARIAD intends to co-promote ridaforolimus in the United States. About Sarcoma Sarcomas are a group of cancers of connective tissue of the body for which there are currently limited","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:16+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120510007091r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/","name":"FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120510007091r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2011-10-05T06:35:00+00:00","dateModified":"2026-08-10T17:01:16+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120510007091r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120510007091r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-inhibitor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"fdbb8227-c873-479c-a545-65b284b225c6","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742082\/revisions"}],"predecessor-version":[{"id":3679218,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742082\/revisions\/3679218"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742082"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}